Our data suggest that IGF2BP3 overexpression identifies a subset of pancreatic ductal adenocarcinomas with an extremely poor outcome and supports the rationale for developing therapies to target the IGF pathway in this cancer. This evidence concerns the gene IGF2BP3 and pancreatic ductal adenocarcinoma.